8-K: Anixa Biosciences and Cleveland Clinic Announce Positive Updated Data from Breast Cancer Vaccine Phase 1 Trial

Anixa Biosciences and Cleveland Clinic presented updated positive data from their Phase 1 breast cancer vaccine trial, showing promising immune responses and safety across multiple cohorts.

Summary

• Anixa Biosciences and Cleveland Clinic have released updated positive data from their Phase 1 clinical trial of a breast cancer vaccine.
• The vaccine targets the alpha-lactalbumin protein, which is expressed in breast cancer cells.
• The Phase 1 trial included three cohorts of patients: women who had completed treatment for triple-negative breast cancer (TNBC), women at high genetic risk of developing breast cancer, and women with TNBC receiving pembrolizumab (Keytruda).
• The vaccine was found to be safe and well-tolerated across all three cohorts, with the most common side effect being injection site irritation.
• Over 70% of patients exhibited protocol-defined immune responses.
• A Phase 2 study is planned to commence in 2025, evaluating the vaccine in the neoadjuvant setting for newly diagnosed breast cancer patients.

Sentiment

Score: 8

Explanation: The document presents very positive results from the Phase 1 trial, with a clear path forward to Phase 2. The safety profile and immune response rates are encouraging, suggesting a high potential for success.

Positives

• The vaccine demonstrated a strong safety profile with minimal side effects.
• The vaccine induced immune responses in a significant majority of patients.
• The positive results support the progression to a Phase 2 trial.
• The vaccine is based on decades of research and has a novel approach to targeting breast cancer.
• The collaboration between Anixa Biosciences and Cleveland Clinic is progressing well.

Negatives

• One patient in the cohort receiving Keytruda experienced a Grade 3 adverse event, which was a greater amount of irritation at one injection site.
• The trial protocol is being amended to provide for a six-month delay after lactation before a patient can be vaccinated.

Risks

• The Phase 2 trial may not yield the same positive results as the Phase 1 trial.
• The vaccine may not be effective in all patients.
• The development of the vaccine is subject to regulatory approvals and may face delays.
• The company may face challenges in securing a strategic partnership for commercialization.
• The company is reliant on the continued collaboration with Cleveland Clinic.

Future Outlook

The company plans to commence a Phase 2 study in 2025 to evaluate the vaccine in the neoadjuvant setting for newly diagnosed breast cancer patients, with the goal of securing a strategic partnership for commercialization.

Management Comments

• G. Thomas Budd, M.D. of Cleveland Clinic stated that they are hoping this can be a true preventive vaccine.
• Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, stated that the data continues to exceed their expectations and they are planning a Phase 2 study.
• Dr. Kumar also mentioned that a successful Phase 2 trial may enable a quicker route to a strategic relationship with a large pharmaceutical partner.

Industry Context

The development of a breast cancer vaccine is a significant advancement in the field of oncology, particularly for triple-negative breast cancer, which has limited treatment options. This announcement positions Anixa Biosciences as a key player in the development of novel cancer immunotherapies.

Comparison to Industry Standards

• The use of alpha-lactalbumin as a target for a breast cancer vaccine is a novel approach, differentiating it from other cancer vaccine development programs.
• The reported immune response rate of over 70% is promising compared to other early-stage cancer vaccine trials.
• The safety profile of the vaccine appears favorable compared to other immunotherapies, which often have more significant side effects.
• The planned Phase 2 trial in the neoadjuvant setting is a common approach for evaluating cancer therapies, allowing for a direct assessment of efficacy.

Related Party Transactions

• Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company.

Stakeholder Impact

• Shareholders will likely view the positive trial results favorably.
• Patients with breast cancer may benefit from this new treatment option.
• The collaboration with Cleveland Clinic strengthens the company's research capabilities.
• Employees may be motivated by the positive progress of the vaccine development.

Next Steps

• Enrollment of additional patients in Cohort 1b is ongoing.
• Immunohistochemistry (IHC) analysis of breast tissue from Cohort 1b will be presented in a future scientific presentation.
• A Phase 2 study is planned to commence in 2025, evaluating the vaccine in the neoadjuvant setting.
• The company will seek a strategic partnership for commercialization.

Key Dates

Keywords

breast cancer vaccine, immunotherapy, clinical trial, Phase 1, Phase 2, triple negative breast cancer, alpha-lactalbumin, Cleveland Clinic, Anixa Biosciences, neoadjuvant, Keytruda